NCT02346253 2026-04-13
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
Phase NA Active not recruiting
Clinical Trials
19 trialsNCT03361735 2026-04-09
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT04484818 2026-03-23
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04455750 2026-02-05
CASPAR
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04126070 2026-01-22
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT03860987 2025-09-08
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04181203 2025-07-30
CARLHA-2
UNICANCER
Phase 3 Active not recruiting
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT00544830 2025-05-07
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00223145 2025-01-27
PCS III
Université de Sherbrooke
Phase 3 Active not recruiting
NCT02685397 2024-12-04
PCS IX
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2/3 Active not recruiting
NCT05003752 2023-03-07
Hypo-Combi
German Oncology Center, Cyprus
Phase 1/2 Active not recruiting
NCT00430183 2023-02-09
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting